Company

Milestones from Founding to Present

1999

Incorporated in the Commonwealth of Virginia as Critical Care Innovations, Inc., as of October 2008, name of Company changed to NuVue Therapeutics, Inc. Still a “C” corporation in May of 1999.

2000

EchoCath, Inc. License and Exclusivity Agreement negotiated and documents approved and signed by EchoCath Board of Directors in January of 2000.

Completed first raise of monies in November 2000, raising $1.47 million in equity from Founder and 9 private investors.

2001

Expand the scope of business to include cancer therapeutic markets.

Acquired 7% equity stake in the cryosurgical company, CryoFlex™, Inc. of West Palm Beach, Florida, in September 2001.

2002

Product specifications and manufacturing costs for first generation“P1” disposable NuVue™ FNA needles and Piezo housing completed, reviewed, and approved in March 2002.
In July 2002, successfully demonstrated at Duke University that the Company’s patented “UGV” technologies allow for the precise placement of pacemaker leads and guide-wires using the next generation 3D ultrasound devices.

Signed Definitive Agreement at the end of September of 2002 with CryoFlex™, Inc. of West Palm Beach, Florida for the Asset Purchase of their three patents for cryosurgical and electrical impedance measurement technologies and trademarks, as well.
 
Signed Definitive Agreement at the end of September of 2002 with EchoCath, Inc. to acquire, through an asset purchase, sixteen patents and all trade marks for their core “UGV” technology including the expanded fields of use; structured Royalty Fee to be 1% of sales after company hits a level of $10 million/ year of EchoCath related products annually, only through end of EchoCath patents

2003

A Definitive Agreement was signed in March of 2003, between Dr. Ruth Katz of M.D. Anderson and Company to incorporate her designs into NuVue’s 2nd generation Fine Needle Aspiration Biopsy Device should it be found to enhance efficacy and repeatability for obtaining Fine Needle Aspirates when integrated with our “UGV”-based technologies.

Exclusive License Agreement (Worldwide) from N.A.S.A. finalized and signed in March of 2003 for twelve Microencapsulation patents.

Marketing evaluation of pre-production “P1” disposable NuVue™ FNA products; completion of Final Product Design and Engineering/Manufacturing Specifications. Decided to hold on disposable development due to monies.

2004-2005

Completion of multiple small animal experiments proving both the principles and concepts of the Company’s integrated IP Technologies.

Submitted the first in a series of additional patents to cover the integrated and combined Methods and Devices the Company developed for its Cryothermally Enhanced/ Microencapsulation Controlled Release Drug and Drug Delivery Systems.

2006

Company’s diversified abilities inherently proven in principle and concept, through extensive animal studies for ; (1) the acquisition of malignant tissues, (2) the positioning of new a newly developed BrightMark site specific tissue marker - Tissue Imaging   System, for the postoperative follow-up of cancer patients and (3) the delivery of numerous cytotoxic substrates as individualized multifunctional chemotherapeutic courses of therapy.

Management led to believe that other therapeutic systems, such as, i.e. Nanotechnologies, monoclonal antibodies and whole cells, e.g. pancreatic and stem cells, as they are found to be advantageous in the diagnosis or therapeutic use with malignant tissues will also be delivered through the Company’s proprietary methodologies.

2007

Raised $ 1.77 Million Dollars, in the first quarter of 2007 with a Convertible Debenture, so the Company could proceed with the development of an R & D project , to miniaturize the Ultrasound guided Visualization Technologies, into a hand held device which would be a one time use, disposable/ consumable. 

Continued research and development on the effects of cryothermal  / cooling of tissues in dual animal studies with Human prostate and Human Lung tumors in xenogenic mice with luminescent Imaging. Proved all principles and concepts pertaining to integration of all the company’s technologies and the synergistic responses found and documented for the first time regarding such integrated methodologies and processes.

2008

Formulated, scribed , and submitted to USPTO  four (4) new patents covering all the proprietary technologies found in 2006 and 2007 animal Research and Development,  2  more papers scribed and submitted to different cancer journals, after patents were submitted and pending. Presented the Company Profile at the ADVAMED meeting in Washington DC, September 2008.

From June of 2007 to present , a complete new generation of enhanced Ultrasound Visualization technologies, NuVue ColorMark™ FNA Biopsy Needles and the miniaturization of such proprietary electronics has been invented, and patent submitted. The company now is ready to come to market, approximately June2009, after funding, with its first NuVue Colormark™ FNA Needles for diagnostic tissue acquisition and the delivery of CryoChemoAblative drugs.